The purpose of this study is to provide medication for opioid use disorder (MOUD) with
buprenorphine and naloxone, or bup/nx, and pre-exposure prophylaxis (PrEP) for HIV prevention
for persons who inject opioids accessing syringe services programs (SSPs), as part of a
comprehensive harm reduction program, and assess the acceptability and feasibility of using
telemedicine to implement the program.
The initial visit will be conducted in person or remotely via telemedicine given COVID-19
protocols at the SSP sites in Charlotte and Wilmington, North Carolina (NC); follow-up visits
will be conducted via telemedicine.